NCT02018926 - Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Mocetinostat

Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle

DRUG

Azacitidine

Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle

Trial Locations (10)

10595

New York Medical College, Valhalla

20057

Georegetown University, Washington D.C.

27705

Duke University Medical Center, Durham

29601

St. Francis Hospital, Greenville

33014

Lakes Research, Miami Lakes

55905

Mayo Clinic, Rochester

78130

Cancer Care Centers of South Texas, New Braunfels

78229

Cancer Care Centers of South Texas, San Antonio

03756

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon

05405

Fletcher Allen Health Care and Vermont Cancer Center, Burlington